Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Jenkins

Showing results (491-500 of 799) with videos related to

Pageof 80
Sort By:
Cancer Genetics and Cytogenetics|September 15, 2007
Myxoinflammatory fibroblastic sarcoma showing t(2;6)(q31;p21.3) as a sole cytogenetic abnormalityCristiane M Ida, Kristen A Rolig, Rachael L Hulshizer, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|January 18, 2002
Loss of p53 and c-myc overrepresentation in stage T(2-3)N(1-3)M(0) prostate cancer are potential markers for cancer progressionJunqi Qian, Kiyoshi Hirasawa, David G Bostwick, et al.
Plos One|January 5, 2012
A carrier for non-covalent delivery of functional beta-galactosidase and antibodies against amyloid plaques and IgM to the brainGobinda Sarkar, Geoffry L Curran, Eric Mahlum, et al.
Obstetrics and Gynecology|February 12, 2014
First-trimester risk factors for preeclampsia development in women initiating aspirin by 16 weeks of gestationDana M Block-Abraham, Ozhan M Turan, Lauren E Doyle, et al.
Archives of Pathology & Laboratory Medicine|October 28, 2020
HER2 Testing for Breast Cancer in the Genomics Laboratory: A Sea Change for Fluorescence In Situ HybridizationKatherine B Geiersbach, Daniel R Sill, Reid G Meyer, et al.
Nanomedicine : Nanotechnology, Biology, and Medicine|October 10, 2018
Cationic carrier peptide enhances cerebrovascular targeting of nanoparticles in Alzheimer's disease brainKristen M Ahlschwede, Geoffry L Curran, Jens T Rosenberg, et al.
Brain Pathology (Zurich, Switzerland)|August 20, 2008
Interphase cytogenetics for 1p19q and t(1;19)(q10;p10) may distinguish prognostically relevant subgroups in extraventricular neurocytomaFausto J Rodriguez, Renan A Mota, Bernd W Scheithauer, et al.
American Journal of Clinical Pathology|January 29, 2013
Comparison of fluorescence in situ hybridization (FISH) and dual-ISH (DISH) in the determination of HER2 status in breast cancerAaron S Mansfield, William R Sukov, Jeanette E Eckel-Passow, et al.
American Journal of Clinical Pathology|December 10, 1999
Detection of p16, RB, CDK4, and p53 gene deletion and amplification by fluorescence in situ hybridization in 96 gliomasA Perry, K Anderl, T J Borell, et al.
The American Journal of Surgical Pathology|March 19, 2008
Ependymal tumors with sarcomatous change ("ependymosarcoma"): a clinicopathologic and molecular cytogenetic studyFausto J Rodriguez, Bernd W Scheithauer, Arie Perry, et al.
Pageof 80

Showing results (491-500 of 799) with videos related to

Sort By:
Pageof 80
Cancer Genetics and Cytogenetics|September 15, 2007
Myxoinflammatory fibroblastic sarcoma showing t(2;6)(q31;p21.3) as a sole cytogenetic abnormalityCristiane M Ida, Kristen A Rolig, Rachael L Hulshizer, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|January 18, 2002
Loss of p53 and c-myc overrepresentation in stage T(2-3)N(1-3)M(0) prostate cancer are potential markers for cancer progressionJunqi Qian, Kiyoshi Hirasawa, David G Bostwick, et al.
Plos One|January 5, 2012
A carrier for non-covalent delivery of functional beta-galactosidase and antibodies against amyloid plaques and IgM to the brainGobinda Sarkar, Geoffry L Curran, Eric Mahlum, et al.
Obstetrics and Gynecology|February 12, 2014
First-trimester risk factors for preeclampsia development in women initiating aspirin by 16 weeks of gestationDana M Block-Abraham, Ozhan M Turan, Lauren E Doyle, et al.
Archives of Pathology & Laboratory Medicine|October 28, 2020
HER2 Testing for Breast Cancer in the Genomics Laboratory: A Sea Change for Fluorescence In Situ HybridizationKatherine B Geiersbach, Daniel R Sill, Reid G Meyer, et al.
Nanomedicine : Nanotechnology, Biology, and Medicine|October 10, 2018
Cationic carrier peptide enhances cerebrovascular targeting of nanoparticles in Alzheimer's disease brainKristen M Ahlschwede, Geoffry L Curran, Jens T Rosenberg, et al.
Brain Pathology (Zurich, Switzerland)|August 20, 2008
Interphase cytogenetics for 1p19q and t(1;19)(q10;p10) may distinguish prognostically relevant subgroups in extraventricular neurocytomaFausto J Rodriguez, Renan A Mota, Bernd W Scheithauer, et al.
American Journal of Clinical Pathology|January 29, 2013
Comparison of fluorescence in situ hybridization (FISH) and dual-ISH (DISH) in the determination of HER2 status in breast cancerAaron S Mansfield, William R Sukov, Jeanette E Eckel-Passow, et al.
American Journal of Clinical Pathology|December 10, 1999
Detection of p16, RB, CDK4, and p53 gene deletion and amplification by fluorescence in situ hybridization in 96 gliomasA Perry, K Anderl, T J Borell, et al.
The American Journal of Surgical Pathology|March 19, 2008
Ependymal tumors with sarcomatous change ("ependymosarcoma"): a clinicopathologic and molecular cytogenetic studyFausto J Rodriguez, Bernd W Scheithauer, Arie Perry, et al.
Pageof 80